Can a new drug outsmart resistant breast cancer?
NCT ID NCT07726342
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink tumors and to find the best dose with the fewest side effects. Participants are randomly assigned to one of two dose levels and receive the drug by infusion every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called SMP-656 given by intravenous infusion
- What this could lead to
- If effective, SMP-656 could offer a new treatment option for people with HER2-positive breast cancer that has stopped responding to current therapies.
- What could go wrong
- This is an early phase II trial with only 60 participants, so results may not apply broadly. Side effects and lack of efficacy are possible risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- New drug targets Hard-to-Treat breast cancer in advanced stage
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer
- PET scan could reveal which breast cancer patients will respond to targeted therapy